{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:23:52Z","timestamp":1777454632356,"version":"3.51.4"},"reference-count":42,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2014,6,24]],"date-time":"2014-06-24T00:00:00Z","timestamp":1403568000000},"content-version":"unspecified","delay-in-days":2458,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:sec><jats:title><jats:bold>Objective:<\/jats:bold><\/jats:title><jats:p>The purpose of present study was to evaluate the efficacy of the addition of reboxetine in patients that had not previously responded, or had done so only partially, over 6 weeks of conventional pharmacological treatment with venlafaxine.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:bold>Methods:<\/jats:bold><\/jats:title><jats:p>This open-label, prospective and multicentric study included 40 outpatients diagnosed with major depressive disorder according to the DSM-IV criteria. Efficacy was assessed using the 21-item Hamilton Depression Rating Scale (HAMD) and the Clinical Global Impression-Improvement (CGI-I). Safety was evaluated by recording spontaneously reported adverse events. Data were analysed on an intent-to-treat basis, using the last-observation-carried-forward method.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:bold>Results:<\/jats:bold><\/jats:title><jats:p>Mean HAMD reduction was 34.9% (<jats:italic>P<\/jats:italic> &lt; 0.0001). The percentages of responders (\u226550% reduction in HAMD) and patients considered as benefiting from complete remission (HAMD \u2264 10 points) at week 6 were 27.5 and 12.5%, respectively. By the end of the treatment, the score of CGI-I decreased 24.8% (<jats:italic>P<\/jats:italic> &lt; 0.0001). Percentage of patient improving (CGI &lt; 4 points) was 47.5%. The most common non-serious adverse events were constipation, nervousness, anxiety and insomnia.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:bold>Conclusion:<\/jats:bold><\/jats:title><jats:p>These findings suggest that the combined treatment of reboxetine and venlafaxine, in venlafaxine-resistant patients, may be an effective and well-tolerated strategy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1601-5215.2007.00187.x","type":"journal-article","created":{"date-parts":[[2007,7,27]],"date-time":"2007-07-27T00:16:02Z","timestamp":1185495362000},"page":"291-296","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":6,"title":["Combined treatment with reboxetine in depressed patients with no response to venlafaxine: a 6-week follow-up study"],"prefix":"10.1017","volume":"19","author":[{"given":"Cecilio","family":"\u00c1lamo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,6,24]]},"reference":[{"key":"S0924270800002593_b19","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199910000-00003"},{"key":"S0924270800002593_b4","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(1996)4:4<169::AID-DA3>3.0.CO;2-A"},{"key":"S0924270800002593_b27","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200010000-00008"},{"key":"S0924270800002593_b2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199701000-00003"},{"key":"S0924270800002593_b17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052964"},{"key":"S0924270800002593_b21","first-page":"106","article-title":"Eficacia de la venlafaxina en pacientes depresivos resistentes o que no toleran inhibidores selectivos de la recaptaci\u00f3n de serotonina","volume":"6","author":"S\u00e1iz-Ruiz","year":"1999","journal-title":"Psiquiatr Biol"},{"key":"S0924270800002593_b18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.06.027"},{"key":"S0924270800002593_b30","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200002000-00006"},{"key":"S0924270800002593_b3","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(05)70293-8"},{"key":"S0924270800002593_b10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1106"},{"key":"S0924270800002593_b42","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519010-00004"},{"key":"S0924270800002593_b36","first-page":"285","article-title":"Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: initial findings","volume":"61","author":"G\u00f3mez","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"S0924270800002593_b16","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0805"},{"key":"S0924270800002593_b9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1997.tb10136.x"},{"key":"S0924270800002593_b35","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039060-00003"},{"key":"S0924270800002593_b24","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(03)00120-9"},{"key":"S0924270800002593_b13","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n0707g"},{"key":"S0924270800002593_b1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1176\/ajp.151.7.979","article-title":"The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey","volume":"151","author":"Blazer","year":"1994","journal-title":"Am J Psychiatry"},{"key":"S0924270800002593_b26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2003.08.001"},{"key":"S0924270800002593_b25","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0302"},{"key":"S0924270800002593_b41","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17041"},{"key":"S0924270800002593_b34","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199503002-00004"},{"key":"S0924270800002593_b5","first-page":"S39","article-title":"Resistant depression: definition and treatment approaches","volume":"51","author":"Nierenberg","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"S0924270800002593_b23","first-page":"5","article-title":"Managing treatment-resistant major depression","volume":"64","author":"Craig","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"S0924270800002593_b40","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549020-00010"},{"key":"S0924270800002593_b8","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(95)00292-8"},{"key":"S0924270800002593_b11","first-page":"36","article-title":"The aims and design of the sequenced treatment alternatives to relieve depression (STAR*D) Study","volume":"12","author":"Gaynes","year":"2005","journal-title":"Prim Psychiatr"},{"key":"S0924270800002593_b22","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0110"},{"key":"S0924270800002593_b32","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0913"},{"key":"S0924270800002593_b39","first-page":"75","article-title":"Eficacia y seguridad de la asociaci\u00f3n de antidepresivos","volume":"30","author":"De La G\u00e1ndara","year":"2002","journal-title":"Actas Esp Psiquiatr"},{"key":"S0924270800002593_b20","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199412000-00008"},{"key":"S0924270800002593_b33","first-page":"180","article-title":"An integration of ethical and clinical considerations in the use of placebos","volume":"24","author":"Stanley","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"S0924270800002593_b38","first-page":"293","article-title":"The pharmacology and mode of action of venlafaxine","volume":"9","author":"Horst","year":"1998","journal-title":"Rev Contemp Pharmacother"},{"key":"S0924270800002593_b31","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2000.02606.x"},{"key":"S0924270800002593_b12","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199911030-00002"},{"key":"S0924270800002593_b7","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199504050-00003"},{"key":"S0924270800002593_b37","first-page":"315","article-title":"Tratamiento de combinaci\u00f3n con reboxetina en pacientes con depresi\u00f3n mayor no respondedores o con respuesta parcial a inhibidores selectivos de la recaptaci\u00f3n de serotonina","volume":"31","author":"Rubio","year":"2003","journal-title":"Actas Esp Psiquiatr"},{"key":"S0924270800002593_b29","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(97)00418-5"},{"key":"S0924270800002593_b6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2005.00677.x"},{"key":"S0924270800002593_b15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.08.012"},{"key":"S0924270800002593_b28","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00291-7"},{"key":"S0924270800002593_b14","first-page":"13","article-title":"Augmentation strategies in depression","volume":"61","author":"Nelson","year":"2000","journal-title":"J Clin Psychiatry"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270800002593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T20:44:14Z","timestamp":1556743454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270800002593\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0924270800002593"],"URL":"https:\/\/doi.org\/10.1111\/j.1601-5215.2007.00187.x","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"value":"0924-2708","type":"print"},{"value":"1601-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Copyright \u00a9 2007 Blackwell Munksgaard","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}